Inside Precision Medicine November 2, 2022
Chris Anderson

Myriad Genetics announced on Tuesday that it acquired consumer-focused prenatal and pediatric genomic test developer Gateway Genomics for $67.5 million in cash. The deal could pay Gateway an additional an additional $32.5 million of cash payments in 2023 and 2024 if certain revenue, volume synergy and EBITDA targets are achieved.

Via the Gateway acquisition, Myriad adds the SneakPeek Early Gender DNA test to its portfolio of women’s health products. According to the companies, SneakPeek is the top selling at-home gender test for expectant families and can deliver results with 99% accuracy only six weeks into the term of a pregnancy. Other products in Myriad’s women’s health line include the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
J&J to shut down massive Bay Area R&D facility less than 18 months after opening it
Molecular “Super Glue”? How Our Body Repairs Broken DNA
Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug
FDA Updates for the Week of Feb 19: Cancer Approval Revoked
FDA Approves Simlandi, Third Interchangeable Humira Biosimilar

Share This Article